Medical device company Medtronic has received the US Food and Drug Administration (FDA) approval for its MiniMed 780G system with the Guardian 4 sensor and SmartGuard technology.

The Guardian 4 Sensor and transmitter used in the system measure glucose levels every five minutes and transfer the data to the insulin pump.

It eliminates the need for finger pricks to calibrate or make diabetes treatment decisions.

Based on continuous insulin data from the CGM sensor, the Insulin Pump of the system makes automatic adjustments and corrections to the patient’s insulin delivery.

The system also features a MiniMed Mio Advance infusion set, which is designed with a pre-loaded inserter for rapid, and easy set changes needing fewer steps.

The infusion set can be worn for up to seven days, doubling wear time to reduce insulin loss and maintain insulin flow and stability, reducing the risk of the infusion set occlusion.

Medtronic said that its MiniMed 780G system facilitates the lowest glucose target setting, where users can as target as low as 100mg/dL dose, in any available automated insulin pump.

The setting closely mimics the average glucose delivery of people not living with diabetes and will automatically deliver basal insulin adjustments and autocorrections to a set target.

Also, the system delivers a user-friendly design, where 94% of users said they are satisfied with the impact the system has on their quality of life.

MiniMed 780G is the only FDA-approved insulin pump system with meal detection technology, for both basal and bolus insulin needs, said the company.

Medtronic Diabetes president and EVP Que Dallara said: “Mealtimes prove to be one of the biggest challenges for people living with type 1 diabetes and now for the first time, the MiniMed 780G system addresses this unmet need with automatic, real-time insulin corrections.

“A lot can happen to blood sugars in the span of an hour or even just a few minutes, so we’ve designed our system for real life – the algorithm adapts to the user and helps compensate for everyday challenges that are quite common around mealtimes.

“We built in features informed by extensive customer feedback, and we’re excited to deliver a system with ease of use at the forefront.”

Earlier this year, Medtronic announced positive results for the MiniMed 780G system from the randomised controlled ADAPT study.

The study evaluated the performance of the MiniMed 780G system compared to multiple daily injections (MDI) used in conjunction with an intermittently scanned CGM (isCGM).

The study results highlighted the benefits of automated insulin therapy over standard therapy.